Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 6/20 | 0.36 |
| ▸ | HTR2A | P28223 | 4/20 | 0.36 |
| ▸ | HTR2B | P41595 | 4/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2266951 | 1.00 | HTR2C (0.36) | HTR2CHTR2AHTR2BRIPK1PDE4B | |
| SCHEMBL2264928 | 0.96 | HTR2C (0.34) | HTR2CHTR2AHTR2BRIPK1PDE4B | |
| SCHEMBL2264920 | 0.96 | HTR2C (0.34) | HTR2CHTR2AHTR2BRIPK1PDE4B | |
| SCHEMBL12366422 | 0.96 | HTR2C (0.34) | HTR2CHTR2AHTR2BRIPK1PDE4B | |
| SCHEMBL2264924 | 0.96 | HTR2C (0.34) | HTR2CHTR2AHTR2BRIPK1PDE4B | |
| SCHEMBL2264931 | 0.96 | HTR2C (0.34) | HTR2CHTR2AHTR2BRIPK1PDE4B | |
| SCHEMBL1853162 | 0.93 | HTR2C (0.36) | HTR2CHTR2AHTR2BRIPK1PDE4B | |
| SCHEMBL1853160 | 0.93 | HTR2C (0.36) | HTR2CHTR2AHTR2BRIPK1PDE4B | |
| SCHEMBL26036401 | 0.93 | HTR2C (0.36) | HTR2CHTR2AHTR2BRIPK1PDE4B | |
| SCHEMBL12366406 | 0.93 | HTR2C (0.40) | HTR2CHTR2AHTR2BRIPK1PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828548-B2 | Liquid-crystal composition | DIC CORPORATION (JP) | 2017-11-28 | — | — | US | disclosed |
| EP-1860089-B1 | DIFLUOROBENZENE DERIVATIVE AND NEMATIC LIQUID CRYSTAL COMPOSITION MAKING USE OF THE SAME | DAINIPPON INK & CHEMICALS (JP) | 2011-12-21 | — | — | EP | disclosed |
| EP-1860089-B1 | DIFLUOROBENZENE DERIVATIVE AND NEMATIC LIQUID CRYSTAL COMPOSITION MAKING USE OF THE SAME | DAINIPPON INK & CHEMICALS (JP) | 2011-12-21 | — | — | EP | disclosed |
| US-8003006-B2 | Difluorobenzene derivative and nematic liquid crystal composition using the same | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2011-08-23 | — | — | US | disclosed |
| US-8003006-B2 | Difluorobenzene derivative and nematic liquid crystal composition using the same | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2011-08-23 | — | — | US | disclosed |
| US-8003006-B2 | Difluorobenzene derivative and nematic liquid crystal composition using the same | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2011-08-23 | — | — | US | disclosed |
| US-20090200514-A1 | DIFLUOROBENZENE DERIVATIVE AND NEMATIC LIQUID CRYSTAL COMPOSITION USING THE SAME | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2009-08-13 | — | — | US | disclosed |
| US-20090200514-A1 | DIFLUOROBENZENE DERIVATIVE AND NEMATIC LIQUID CRYSTAL COMPOSITION USING THE SAME | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2009-08-13 | — | — | US | disclosed |
| US-20090200514-A1 | DIFLUOROBENZENE DERIVATIVE AND NEMATIC LIQUID CRYSTAL COMPOSITION USING THE SAME | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2009-08-13 | — | — | US | disclosed |
| EP-1860089-A1 | DIFLUOROBENZENE DERIVATIVE AND NEMATIC LIQUID CRYSTAL COMPOSITION MAKING USE OF THE SAME | Dainippon Ink and Chemicals, Incorporated (JP) | 2007-11-28 | — | — | EP | disclosed |
| EP-1860089-A1 | DIFLUOROBENZENE DERIVATIVE AND NEMATIC LIQUID CRYSTAL COMPOSITION MAKING USE OF THE SAME | Dainippon Ink and Chemicals, Incorporated (JP) | 2007-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090200514-A1 | DIFLUOROBENZENE DERIVATIVE AND NEMATIC LIQUID CRYSTAL COMPOSITION USING THE SAME | TRPV2, HCN2, DVL1 | HTR2C 2621/4885HTR2A 3375/4885HTR2B 2616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.